Literature DB >> 34789471

High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.

Katharine K Brieger1, Minh Tung Phung1, Bhramar Mukherjee2, Kelly M Bakulski1, Hoda Anton-Culver3, Elisa V Bandera4, David D L Bowtell5,6, Daniel W Cramer7,8, Anna DeFazio9,10, Jennifer A Doherty11, Sian Fereday5,6, Renée Turzanski Fortner12, Aleksandra Gentry-Maharaj13, Ellen L Goode14, Marc T Goodman15,16, Holly R Harris17,18, Keitaro Matsuo19,20, Usha Menon13, Francesmary Modugno21,22,23, Kirsten B Moysich24, Bo Qin4, Susan J Ramus25,26, Harvey A Risch27, Mary Anne Rossing17,18, Joellen M Schildkraut28, Britton Trabert29, Robert A Vierkant30, Stacey J Winham31, Nicolas Wentzensen29, Anna H Wu32, Argyrios Ziogas3, Lilah Khoja1, Kathleen R Cho33, Karen McLean34, Jean Richardson32,35, Bronwyn Grout35, Anne Chase35, Cindy McKinnon Deurloo35, Kunle Odunsi36, Brad H Nelson37, James D Brenton38, Kathryn L Terry7,8, Paul D P Pharoah39,40, Andrew Berchuck41, Gillian E Hanley42, Penelope M Webb43, Malcolm C Pike32,44, Celeste Leigh Pearce.   

Abstract

BACKGROUND: There is suggestive evidence that inflammation is related to ovarian cancer survival. However, more research is needed to identify inflammation-related factors that are associated with ovarian cancer survival and to determine their combined effects.
METHODS: This analysis used pooled data on 8,147 women with invasive epithelial ovarian cancer from the Ovarian Cancer Association Consortium. The prediagnosis inflammation-related exposures of interest included alcohol use; aspirin use; other nonsteroidal anti-inflammatory drug use; body mass index; environmental tobacco smoke exposure; history of pelvic inflammatory disease, polycystic ovarian syndrome, and endometriosis; menopausal hormone therapy use; physical inactivity; smoking status; and talc use. Using Cox proportional hazards models, the relationship between each exposure and survival was assessed in 50% of the data. A weighted inflammation-related risk score (IRRS) was developed, and its association with survival was assessed using Cox proportional hazards models in the remaining 50% of the data.
RESULTS: There was a statistically significant trend of increasing risk of death per quartile of the IRRS [HR = 1.09; 95% confidence interval (CI), 1.03-1.14]. Women in the upper quartile of the IRRS had a 31% higher death rate compared with the lowest quartile (95% CI, 1.11-1.54).
CONCLUSIONS: A higher prediagnosis IRRS was associated with an increased mortality risk after an ovarian cancer diagnosis. Further investigation is warranted to evaluate whether postdiagnosis exposures are also associated with survival. IMPACT: Given that pre- and postdiagnosis exposures are often correlated and many are modifiable, our study results can ultimately motivate the development of behavioral recommendations to enhance survival among patients with ovarian cancer. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 34789471      PMCID: PMC9281656          DOI: 10.1158/1055-9965.EPI-21-0977

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.090


  65 in total

1.  A comparison of inclusive and restrictive strategies in modern missing data procedures.

Authors:  L M Collins; J L Schafer; C M Kam
Journal:  Psychol Methods       Date:  2001-12

2.  Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer.

Authors:  R B Ness; J A Grisso; C Cottreau; J Klapper; R Vergona; J E Wheeler; M Morgan; J J Schlesselman
Journal:  Epidemiology       Date:  2000-03       Impact factor: 4.822

Review 3.  Cigarette smoking and inflammation: cellular and molecular mechanisms.

Authors:  J Lee; V Taneja; R Vassallo
Journal:  J Dent Res       Date:  2011-08-29       Impact factor: 6.116

4.  Pelvic inflammatory disease and the risk of ovarian cancer: a meta-analysis.

Authors:  Zhiyi Zhou; Fangfang Zeng; Jianhui Yuan; Jinling Tang; Graham A Colditz; Shelley S Tworoger; Britton Trabert; Xuefen Su
Journal:  Cancer Causes Control       Date:  2017-03-24       Impact factor: 2.506

5.  Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium.

Authors:  Holly R Harris; Ana Babic; Penelope M Webb; Christina M Nagle; Susan J Jordan; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Francesmary Modugno; Roberta B Ness; Kirsten B Moysich; Susanne K Kjær; Estrid Høgdall; Allan Jensen; Joellen M Schildkraut; Andrew Berchuck; Daniel W Cramer; Elisa V Bandera; Nicolas Wentzensen; Joanne Kotsopoulos; Steven A Narod; Catherine M Phelan; John R McLaughlin; Hoda Anton-Culver; Argyrios Ziogas; Celeste L Pearce; Anna H Wu; Kathryn L Terry
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-15       Impact factor: 4.254

Review 6.  Ovarian cancer epidemiology in the era of collaborative team science.

Authors:  Rikki A Cannioto; Britton Trabert; Elizabeth M Poole; Joellen M Schildkraut
Journal:  Cancer Causes Control       Date:  2017-03-10       Impact factor: 2.506

Review 7.  Chronic inflammation and mutagenesis.

Authors:  Lynnette R Ferguson
Journal:  Mutat Res       Date:  2010-03-17       Impact factor: 2.433

8.  Genetic variation in the one-carbon transfer pathway and ovarian cancer risk.

Authors:  Linda E Kelemen; Thomas A Sellers; Joellen M Schildkraut; Julie M Cunningham; Robert A Vierkant; V Shane Pankratz; Zachary S Fredericksen; Madhura K Gadre; David N Rider; Mark Liebow; Ellen L Goode
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

Review 9.  Effect of hormone replacement therapy on inflammatory biomarkers.

Authors:  Panagiota Georgiadou; Effihia Sbarouni
Journal:  Adv Clin Chem       Date:  2009       Impact factor: 5.394

Review 10.  The influence of reproductive and hormonal factors on ovarian cancer survival.

Authors:  C M Nagle; C J Bain; A C Green; P M Webb
Journal:  Int J Gynecol Cancer       Date:  2007-07-21       Impact factor: 3.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.